Why Become an EANO Member?
The European Association of Neuro-Oncology (EANO) is the multidisciplinary society in Europe covering all aspects of Neuro-Oncology, including diagnosis and treatment of brain tumor patients across all ages, effects of systemic cancer and its treatment on the nervous system, nursing issues, and general education in Neuro-Oncology.
Further, EANO has initiated the generation of multidisciplinary guidelines in various fields of neuro-oncology, e.g., malignant glioma and primary CNS lymphoma.
EANO has taken the lead in moving forward the World Federation of Neuro-Oncology Societies (WFNOS), together with our major partner societies, Society of Neuro-Oncology in the US (SNO) and the Asian Society of Neuro-Oncology (ASNO).
EANO is known for its scientific as well as educational meetings with 'state of the art' lectures covering the broad spectrum of all disciplines in Neuro-Oncology.
Being an EANO member will thus provide you with a lot of privileges and above all insures that you are part of a growing and increasingly influential society that shapes Neuro-Oncology in Europe and beyond.
for the EANO Board
Join the EANO Youngsters!
Be informed what is going on in the EANO Youngster Network and stay connected via the "EANO Youngsters" facebook group!
Save the date for the upcoming EANO Youngster Networking Event, May 5, 2017, 8pm Zurich, Switzerland!
EANO Annual Report 2016
With this report, EANO would like to inform you about its activities over the past 12 months. In
addition, the association is grateful for all your support, especially withthe EANO conference in Mannheim. The term of a new executive board has started and they will continue with foci on EANO meetings,
international collaborations and guidelines.
WFNOS Magazine, Issue 3!
Content: Trigger symptoms at the end of life in brain tumor patients ; Updated WHO Classifi cation of Embryonal Tumors of the CNS 2016— Toward Precision Diagnostics by Integration of Histological and Molecular Features; Thromboembolic Complications in Patients with Gliomas; A phase III randomized double-blind, controlled study of ICT-107 with maintenance temozolomide in newly diagnosed glioblastoma following resection and concomitant temozolomide chemoradiotherapy...
click here here to read the whole issue